<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00999336</url>
  </required_header>
  <id_info>
    <org_study_id>08-016</org_study_id>
    <nct_id>NCT00999336</nct_id>
  </id_info>
  <brief_title>A Study to Determine the Pharmacokinetics, Pharmacodynamics, and Tolerabiltiy of Betrixaban in Patients With Mild, Moderate, and Severe Renal Impairment</brief_title>
  <official_title>Pharmacokinetics, Pharmacodynamics, and Tolerability of Betrixaban Administered Orally in Subjects With Normal and Reduced Renal Function.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Portola Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Portola Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare the pharmacokinetics, pharmacodynamics, and
      tolerability of betrixaban in patients with mild, moderate, and severe renal impairment to
      healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of betrixaban</measure>
    <time_frame>8 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety assessments will include vital signs, electrocardiograms and adverse events</measure>
    <time_frame>17 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measures of anti-coagulation</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Renal Impairment</condition>
  <arm_group>
    <arm_group_label>Group H</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy subjects matched to the renal impairment groups</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with mild renal impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with moderate renal impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with severe renal impairment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betrixaban</intervention_name>
    <description>80 mg betrixaban qd for 8 days</description>
    <arm_group_label>Group H</arm_group_label>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to understand and sign the written informed consent.

          -  Subjects should have either normal renal function or have stable renal disease

        Exclusion Criteria:

          -  Subjects require dialysis

          -  Evidence of active bleeding or bleeding disorder

          -  Unstable or clinically significant other disorders such as respiratory, hepatic,
             metabolic, psychiatric or gastrointestinal disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>APEX GmbH</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2009</study_first_submitted>
  <study_first_submitted_qc>October 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2009</study_first_posted>
  <last_update_submitted>September 23, 2010</last_update_submitted>
  <last_update_submitted_qc>September 23, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 27, 2010</last_update_posted>
  <responsible_party>
    <name_title>Eduard Gorina, MD/Senior Director, Clinical Development</name_title>
    <organization>Portola Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Betrixaban</keyword>
  <keyword>Renal impairment</keyword>
  <keyword>Healthy</keyword>
  <keyword>Kidney dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betrixaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

